Title
Li vs. Spouses Soliman
Case
G.R. No. 165279
Decision Date
Jun 7, 2011
An 11-year-old with osteosarcoma died after chemotherapy; parents sued for negligence, but the court ruled the doctor adequately informed them of risks and treatment was not the cause of death.
medical malpractice
suit
parents

Case Summary (G.R. No. 165279)

Factual Background

The Solimans’ eleven-year-old daughter, Angelica, was diagnosed on July 7, 1993 with osteosarcoma after biopsy at St. Luke’s Medical Center. Her right leg was amputated as primary treatment by Dr. Jaime Tamayo, who referred the patient for adjuvant chemotherapy to Dr. Rubi Li, a medical oncologist. On August 19, 1993 petitioner intravenously began a chemotherapy regimen of Cisplatin, Doxorubicin and Cosmegen. Angelica developed progressive complications during hospitalization and died on September 1, 1993, eleven days after the first chemotherapy cycle. A PNP Crime Laboratory autopsy reported cause of death as “Hypovolemic shock secondary to multiple organ hemorrhages and Disseminated Intravascular Coagulation,” while the hospital death certificate listed osteosarcoma, status post amputation, and status post chemotherapy.

Trial Court Proceedings

On February 21, 1994 respondents sued Dr. Rubi Li, Dr. Leo Marbella, St. Luke’s Medical Center and others for negligence and for failure to disclose the risks of chemotherapy, alleging that petitioner assured them of a high chance of cure and mentioned only minor side effects. The Regional Trial Court dismissed the complaint in its September 5, 1997 Decision, finding that petitioner observed proper procedures and employed her skill in administering chemotherapy and that respondents failed to prove negligence in the administration. The RTC ordered respondents to pay an unpaid hospital bill of P139,064.43. The trial court relied heavily on testimonial evidence and noted the non-production of most medical records.

Court of Appeals Ruling

On appeal the Court of Appeals affirmed the RTC’s finding that petitioner was not negligent in the technical administration of chemotherapy but reversed insofar as the trial court had not found a failure in disclosure. The CA held that petitioner had failed to fully explain all known material side effects and risks of chemotherapy to the Solimans and that, had full disclosure been made, the parents might have chosen otherwise. The CA awarded actual damages of P139,064.43, funeral expenses of P9,828.00, moral damages of P200,000.00, exemplary damages of P50,000.00 and attorney’s fees of P30,000.00, and denied reconsideration of that modification.

Issue Presented to the Supreme Court

The principal legal issue presented was whether Dr. Rubi Li could be held liable for failing to fully disclose the material risks of chemotherapy, including the possibility of death, when the courts below found no negligence in the technical administration of chemotherapy and where respondents did not produce competent oncological expert testimony or the patient’s full medical records.

Petitioner’s Contentions

Petitioner maintained that she was not negligent in administering chemotherapy and that she had explained to the Solimans the general side effects of chemotherapy, including lowered white and red blood cells and platelets, hair loss, nausea, and potential organ damage. She argued that specific outcomes vary with each patient’s constitution and that she could not predict individual responses. Petitioner attributed Angelica’s death to overwhelming sepsis due to the underlying malignancy and poor host defenses rather than to improper administration of chemotherapy. She also pointed to her qualifications and experience as an oncologist and to the absence of medical records or competent expert testimony by respondents.

Respondents’ Contentions

Respondents alleged that petitioner assured them of a high likelihood of recovery (expressed as 95% in their testimony) and that she disclosed only three minor side effects, which induced their consent. They argued that petitioner failed to warn them of serious complications that occurred—such as sepsis, severe bleeding from platelet depletion, and death—and that full disclosure would have led them to refuse chemotherapy or pursue alternative courses. Respondents presented a PNP medico-legal officer and a DOH medical specialist as witnesses to link the drugs to platelet reduction and fatal bleeding.

Supreme Court Majority Disposition

The Supreme Court granted the petition for review on certiorari, set aside the Court of Appeals Decision dated June 15, 2004 and its September 1, 2004 Resolution, and reinstated and upheld the Regional Trial Court Decision dated September 5, 1997. No costs were imposed.

Supreme Court Majority Reasoning

The Court first restated the legal contours of the doctrine of informed consent, tracing its evolution from the battery-oriented cases such as Schoendorff v. Society of New York Hospital through negligence-based doctrines exemplified by Canterbury v. Spence and Cobbs v. Grant, and reiterated the four essential elements of an informed-consent malpractice action: duty to disclose material risks; failure to disclose; causation of the patient’s consent by that failure; and injury caused by the proposed treatment. The Court emphasized that many issues in informed-consent cases require expert testimony because the identification and probability of medical risks are technical matters. On the record before it the Court concluded that there was adequate disclosure of the general, material risks of chemotherapy. The majority noted that petitioner had informed the parents that chemotherapy may lower blood counts (including platelets), may affect organs, and may cause other systemic effects, and that respondents, already apprised by prior consultations and surgery that Angelica’s immune defenses were weak, could reasonably be expected to understand that severe complications, including death, could not be excluded from such therapy. The majority found the respondents’ claim that petitioner had represented a 95% chance of cure unlikely and of little probative value. The Court also held that respondents failed to present competent expert evidence to establish (a) the standard of disclosure that should have governed chemotherapy in this case and (b) a causal link showing that the chemotherapy proximately caused Angelica’s death. The Court observed that the two expert witnesses called by respondents—Dr. Jesusa Nieves-Vergara and Dr. Melinda Balmaceda—were not oncologists and thus were not competent to establish the oncological standard of care or to determine causation from chemotherapy, and that Dr. Vergara’s autopsy-based conclusions relied on an oncologist’s opinion and thus lacked the necessary foundation. The Court further noted the non-production of the patient’s medical records and declined to adopt a categorical standard of disclosure in light of the evolving nature of the doctrine and the absence of expert proof. On these grounds the Court held that the CA erred in finding petitioner liable for lack of informed consent and reinstated the RTC judgment dismissing the complaint.

Dissenting Opinion (Carpio, J.)

Justice Carpio dissented. He concluded that Dr. Rubi Li failed to obtain the informed consent of

...continue reading

Analyze Cases Smarter, Faster
Jur helps you analyze cases smarter to comprehend faster, building context before diving into full texts. AI-powered analysis, always verify critical details.

About Privacy Terms